Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01436955 · ClinicalTrials.gov registry record · Phase 1
A Study of RG1662 in Individuals With Down Syndrome
A Phase 1 study of Down Syndrome, sponsored by Hoffmann-La Roche.
- Completed
- Registry status
- Phase 1
- Development phase
- 35
- Enrollment target
- 9
- Study locations
NCT01436955: Completed Phase 1 study of Down Syndrome, sponsored by Hoffmann-La Roche.
NCT01436955 is a Phase 1 study of Down Syndrome that has completed, run by Hoffmann-La Roche. The registered enrollment target is 35 participants, below the 2,471-participant average among 54 other Down Syndrome trials with a reported enrollment target (99% lower). The trial reports 9 study locations across 9 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT01436955, a Phase 1 study of Down Syndrome, has completed, sponsored by Hoffmann-La Roche.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 35 participants
- Enrollment target
- 9
- Study locations
Study Summary
This multi-center, randomized double-blind, placebo-controlled study will assess the safety and tolerability of RG1662 in individuals with Down Syndrome. Eligible subjects will be randomized in cohorts to receive either multiple oral doses of RG1662 or placebo. Anticipated time on study treatment is 38 days.
Conditions Studied
Interventions
- DRUG Placebo
- DRUG RG1662
Study Locations (9)
Arizona
- - Phoenix
Arkansas
- - Little Rock
California
- - La Jolla
Colorado
- - Aurora
Georgia
- - Decatur
Illinois
- - Chicago
Maryland
- - Baltimore
North Carolina
- - Durham
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 35 participants |
| Start Date | 2011-11 |
| Est. Completion | 2013-09 |
| Phase | Phase 1 |
What the finished NCT01436955 record still lists
NCT01436955 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 35 participants, a relatively small participant target, below the 2,471-participant average among 54 other Down Syndrome trials with a reported enrollment target (99% lower).
The record links to 1 condition, with Down Syndrome appearing as the primary indexed condition, and to 2 interventions - of which Placebo is the first listed.
NCT01436955 lists 9 locations in 9 states (Arizona, Arkansas, California).
Frequently Asked Questions
What is clinical trial NCT01436955 about?
NCT01436955 is a clinical study titled "A Study of RG1662 in Individuals With Down Syndrome". This multi-center, randomized double-blind, placebo-controlled study will assess the safety and tolerability of RG1662 in individuals with Down Syndrome. Eligible subjects will be randomized in cohorts to receive either multiple oral doses of RG1662 or placebo. Anticipated time on study treatment is...
What is the current status of trial NCT01436955?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 35 participants. The study started on 2011-11. Estimated completion is 2013-09.
What conditions does trial NCT01436955 study?
This clinical trial studies the following conditions: Down Syndrome.
What interventions are being tested in trial NCT01436955?
The interventions under investigation include: Placebo (DRUG), RG1662 (DRUG).
Who is sponsoring clinical trial NCT01436955?
This trial is sponsored by Hoffmann-La Roche, which has 909 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT01436955 being conducted?
This trial has 9 study locations across Arizona, Arkansas, California, Colorado, Georgia. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Down Syndrome
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT01436955's enrollment target sits among peer trials
35 40th of 54 higher than 15 of 54 other Down Syndrome trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Down Syndrome trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Safety, Tolerability and Immunogenicity of ACI-24 Vaccine in Adults With Down Syndrome
COMPLETED · Phase 1
-
Physical Activity and Community EmPOWERment Project
RECRUITING · NA
-
Treatment of Obstructive Sleep Apnea With Personalized Surgery in Children With Down Syndrome (TOPS-DS)
RECRUITING · NA
-
Brain Outcomes With Lifestyle Change in Down Syndrome
RECRUITING · NA
-
Trial-Ready Cohort-Down Syndrome (TRC-DS)
RECRUITING
-
The Human Trisome Project
RECRUITING
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT01697371 · 35 participants · NA
Proton Therapy in the Treatment of Liver Metastases
- NCT01940757 · 35 participants · Phase 1
Experimental Infection of Hookworm-naïve Adults With Dermally-applied Infectious Necator Americanus Hookworm Larvae
- NCT02235857 · 35 participants · NA
Post Approval Study of Liposorber LA-15 System for the Treatment of Focal Segmental Glomerulosclerosis in Children
- NCT02637934 · 35 participants · Phase 1
Phase I Pilot Study of Biodistribution, Metabolism and Excretion of Novel Radiotracer [18F]Fluorthanatrace (FTT) by PET/CT
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia